Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today reported promising interim clinical results from the ongoing Phase 1/2a studies of its two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III (APOC3) being developed as a potential treatment for patients with severe hypertriglyceridemia, and ARO-ANG3 targeting angiopoietin like protein 3 (ANGPTL3) being developed as a potential treatment for dyslipidemias and metabolic diseases.

Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3

Pasadena. CA | Posted on February 5th, 2020

Javier San Martin, M.D., chief medical officer at Arrowhead, said: “The interim results from the multiple-dose portion of the Phase 1 studies of Arrowhead’s cardiometabolic candidates ARO-APOC3 and ARO-ANG3 are highly encouraging and support our belief that RNAi may be the optimal mechanism to inhibit APOC3 and ANGPTL3. We achieved high levels of APOC3 and ANGPTL3 protein knockdown, which led to impressive reductions in triglycerides and other lipid parameters. In addition, the long duration of effect of ARO-APOC3 and ARO-ANG3 enables a convenient once every 4 months or, possibly, once every 6 months dosing regimen, which also has the potential to improve patient compliance over other agents and mechanisms that require more frequent dosing. From a safety and tolerability perspective, both ARO-ANG3 and ARO-APOC3 data continue to look similar to our other TRiM™ candidates. There have been no drug-related discontinuations, and the most common adverse events reported were headache, respiratory tract infections, and local injection site reactions. This high level of pharmacologic activity with good safety and tolerability to date is precisely what we were hoping for. We look forward to further investigating the potential for ARO-APOC3 and ARO-ANG3 to provide clinical benefits in patients.”

Key interim results from the multiple-dose portion of the AROAPOC31001 Phase 1 clinical study of ARO-APOC3 include the following:

Severe hypertriglyceridemia patients with at least 29 days of data after receiving the first dose (50 mg dose, n=3)
Mean maximum reductions in APOC3 of 97%
Mean maximum reductions in triglycerides (TG) of 95%
Mean maximum absolute reduction in TG of -3183 mg/dL
Key interim results from the multiple-dose portion of the AROANG1001 Phase 1 clinical study of ARO-ANG3 include the following:

Hypercholesterolemia patients on a stable LDL-C lowering treatment regimen including statins, with or without ezetimibe, and some receiving PCSK9 inhibitors, with at least 29 days of data after receiving the first dose (100-300 mg dose, n=22)
Mean maximum reductions in ANGPTL3 of 79-88%
Mean maximum reductions in LDL-C of 39-42%
Hypertriglyceridemia patients with at least 29 days of data after receiving the first dose (200 mg dose, n=5)
Mean maximum reductions in ANGPTL3 of 83%
Mean maximum reductions in TG of 79%

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

First human trial shows ‘wonder’ material can be developed safely: A revolutionary nanomaterial with huge potential to tackle multiple global challenges could be developed further without acute risk to human health, research suggests February 16th, 2024

Detecting breast cancer through a spit test February 16th, 2024

New chip opens door to AI computing at light speed February 16th, 2024

HKUST researchers develop new integration technique for efficient coupling of III-V and silicon February 16th, 2024

Govt.-Legislation/Regulation/Funding/Policy

New chip opens door to AI computing at light speed February 16th, 2024

Electrons screen against conductivity-killer in organic semiconductors: The discovery is the first step towards creating effective organic semiconductors, which use significantly less water and energy, and produce far less waste than their inorganic counterparts February 16th, 2024

Discovery of new Li ion conductor unlocks new direction for sustainable batteries: University of Liverpool researchers have discovered a new solid material that rapidly conducts lithium ions February 16th, 2024

A battery’s hopping ions remember where they’ve been: Seen in atomic detail, the seemingly smooth flow of ions through a battery’s electrolyte is surprisingly complicated February 16th, 2024

Nanomedicine

Detecting breast cancer through a spit test February 16th, 2024

Superbug killer: New synthetic molecule highly effective against drug-resistant bacteria February 16th, 2024

Researchers develop technique to synthesize water-soluble alloy nanoclusters January 12th, 2024

Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024

Announcements

Detecting breast cancer through a spit test February 16th, 2024

New chip opens door to AI computing at light speed February 16th, 2024

HKUST researchers develop new integration technique for efficient coupling of III-V and silicon February 16th, 2024

Electrons screen against conductivity-killer in organic semiconductors: The discovery is the first step towards creating effective organic semiconductors, which use significantly less water and energy, and produce far less waste than their inorganic counterparts February 16th, 2024

Nanobiotechnology

Detecting breast cancer through a spit test February 16th, 2024

Superbug killer: New synthetic molecule highly effective against drug-resistant bacteria February 16th, 2024

Researchers develop technique to synthesize water-soluble alloy nanoclusters January 12th, 2024

Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project